Myriad Genetics Inc (MYGN)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

320 WAKARA WAY SALT LAKE CITY, UT 84108

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Data based on most recent fiscal year report
Market Cap2.113 Billion Shares Outstanding74.39 Million Avg Volume1.429 Million
1-Yr BETA vs S&P TR1.569 Current Ratio2.96 Quick Ratio2.69
View SEC Filings from MYGN instead.

View recent insider trading info

Funds Holding MYGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MYGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

5.9 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

1.3 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HENDERSON JOHN T

  • Director
0 2020-01-02 2

FORD ALEXANDER PRESIDENT, MWH

  • Officer
149,711 2019-12-26 3

GILBERT WALTER PHD

  • Director
54,150 2019-12-13 2

DREISMANN HEINRICH

  • Director
54,790 2019-12-05 1

PHANSTIEL S. LOUISE

  • Director
56,790 2019-12-05 1

BEST LAWRENCE C

  • Director
60,790 2019-12-05 1

LANGER DENNIS

  • Director
60,790 2019-12-05 1

NEWCOMER LEE NISLEY

  • Director
11,687 2019-12-05 2

REITAN COLLEEN F

  • Director
11,687 2019-12-05 2

HAGSTROM WILLIAM A

  • Director
15,385 2019-12-03 0

LANCHBURY JERRY S CHIEF SCIENTIFIC OFFICER

  • Officer
183,440 2019-09-30 3

CAPONE MARK CHRISTOPHER PRESIDENT & C.E.O.

  • Officer
522,216 2019-09-30 3

KING GARY A. EXEC. VP INTERNATIONAL OPS

  • Officer
148,397 2019-09-30 3

MCDADE RALPH L PRESIDENT MYRIAD RBM, INC.

  • Officer
142,095 2019-09-30 3

RIGGSBEE RICHARD BRYAN CHIEF FINANCIAL OFFICER

  • Officer
144,204 2019-09-30 4

TOBIN BERNARD PRESIDENT CRESCENDO BIOSCIENCE

  • Officer
160,636 2019-09-30 3

VERRATTI MARK PRESIDENT ASSUREX HEALTH INC.

  • Officer
79,059 2019-09-30 2

LAMBERT NICOLE PRESIDENT, MGL

  • Officer
63,504 2019-09-30 3

JACKSON BENJAMIN E.V.P., GENERAL COUNSEL

  • Officer
55,996 2019-09-30 3

DROSOS VIRGINIA CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
232,181 2019-09-06 0

MARSH RICHARD M E.V.P., GENERAL COUNSEL

  • Officer
144,174 2018-09-30 0

SANDERS WALTER LLOYD PRESIDENT MYRIAD ONCOLOGY

  • Officer
36,195 2018-09-30 0

WENSTRUP RICHARD CHIEF MEDICAL OFFICER

  • Officer
22,992 2018-03-15 0

MELDRUM PETER D

  • Director
7,800 2017-05-04 0

BELLE GERALD P.

  • Director
275,617 2015-06-03 0

EVANS JAMES S CHIEF FINANCIAL OFFICER

  • Officer
48,128 2014-09-30 0

HARRISON ROBERT GARDNER CHIEF INFORMATION OFFICER

  • Officer
25,844 2014-09-17 0

HART JAYNE B. EXECUTIVE VP HUMAN RESOURCES

  • Officer
26,193 2014-09-17 0

ROGERS RONALD S. EXEC VP CORP COMMUNICATIONS

  • Officer
16,000 2014-09-17 0

ATTIYEH ROBERT S

  • Director
50,249 2014-08-23 0

BENSON T CRAIG PRESIDENT, MYRIAD RBM

  • Officer
0 2013-09-17 0

HOBDEN ADRIAN N PRESIDENT AND CEO

  • Officer
  • Director
208,372 2010-09-24 0

LASLIE W WAYNE CHIEF OPERATING OFFICER

  • Officer
57,254 2010-09-24 0

WILSON LINDA S

  • Director
2,500 2010-01-07 0

SKOLNICK MARK H CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
549,001 2009-11-04 0

CRITCHFIELD GREGORY C PRESIDENT MYRIAD GENETIC LABS

  • Officer
0 2009-09-15 0

HOCKETT WILLIAM A III V. P. OF CORP COMMUNICATIONS

  • Officer
0 2008-09-10 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

FORD ALEXANDER - Officer PRESIDENT, MWH

2019-12-26 M 1,307 d 2,693 149,711.00 direct yes

FORD ALEXANDER - Officer PRESIDENT, MWH

2019-12-26 M 1,307 $15.98 a 149,711 149,711.00 direct yes

GILBERT WALTER PHD - Director

2019-12-13 P 5,860 $25.60 a 54,150 54,150.00 direct

LANGER DENNIS - Director

2019-12-05 A 11,687 a 60,790 60,790.00 direct

NEWCOMER LEE NISLEY - Director

2019-12-05 A 11,687 a 11,687 11,687.00 direct

DREISMANN HEINRICH - Director

2019-12-05 A 11,687 a 54,790 54,790.00 direct

REITAN COLLEEN F - Director

2019-12-05 A 11,687 a 11,687 11,687.00 direct

BEST LAWRENCE C - Director

2019-12-05 A 11,687 a 60,790 60,790.00 direct

HENDERSON JOHN T - Director

2019-12-05 A 11,687 a 76,040 78,090.00 direct

PHANSTIEL S. LOUISE - Director

2019-12-05 A 11,687 a 51,790 56,790.00 direct

GILBERT WALTER PHD - Director

2019-12-05 A 11,687 a 48,290 48,290.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments